Aerie Pharmaceuticals Stock Price To Earning
| AERIDelisted Stock | USD 15.25 0.01 0.07% |
Aerie Pharmaceuticals fundamentals help investors to digest information that contributes to Aerie Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aerie Stock. The fundamental analysis module provides a way to measure Aerie Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aerie Pharmaceuticals stock.
Aerie |
Aerie Pharmaceuticals Company Price To Earning Analysis
Aerie Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Aerie Pharmaceuticals Price To Earning | (19.00) X |
Most of Aerie Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aerie Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Aerie Pharmaceuticals has a Price To Earning of -19.0 times. This is 173.53% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The price to earning for all United States stocks is 166.16% higher than that of the company.
Aerie Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aerie Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aerie Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aerie Pharmaceuticals by comparing valuation metrics of similar companies.Aerie Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Aerie Fundamentals
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 | |||
| Profit Margin | (0.17) % | |||
| Operating Margin | (0.12) % | |||
| Current Valuation | 918.14 M | |||
| Shares Outstanding | 49.42 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Number Of Shares Shorted | 1.52 M | |||
| Price To Earning | (19.00) X | |||
| Price To Book | 34.26 X | |||
| Price To Sales | 3.52 X | |||
| Revenue | 194.13 M | |||
| Gross Profit | 167.29 M | |||
| EBITDA | (7.81 M) | |||
| Net Income | (74.81 M) | |||
| Cash And Equivalents | 184.37 M | |||
| Cash Per Share | 3.73 X | |||
| Total Debt | 234.53 M | |||
| Debt To Equity | 9.41 % | |||
| Current Ratio | 2.60 X | |||
| Book Value Per Share | 0.51 X | |||
| Cash Flow From Operations | (99.15 M) | |||
| Short Ratio | 1.91 X | |||
| Earnings Per Share | (1.47) X | |||
| Target Price | 15.35 | |||
| Number Of Employees | 376 | |||
| Beta | -0.062 | |||
| Market Capitalization | 753.62 M | |||
| Total Asset | 431.39 M | |||
| Retained Earnings | (919.58 M) | |||
| Working Capital | 121.31 M | |||
| Current Asset | 138.43 M | |||
| Current Liabilities | 17.12 M | |||
| Z Score | -4.8 | |||
| Net Asset | 431.39 M |
About Aerie Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aerie Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aerie Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aerie Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Aerie Stock
If you are still planning to invest in Aerie Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aerie Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |